Safety and acceptability of Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 in Bangladeshi infants: a phase I randomized clinical trial

Yana Emmy Hoy-Schulz, Kaniz Jannat, Thomas Roberts, Saira Husain Zaidi, Leanne Unicomb, Stephen Luby, Julie Parsonnet, Yana Emmy Hoy-Schulz, Kaniz Jannat, Thomas Roberts, Saira Husain Zaidi, Leanne Unicomb, Stephen Luby, Julie Parsonnet

Abstract

Background: Probiotics have rarely been studied in young healthy infants from low-income countries. This phase I study investigated the safety and acceptability of two probiotics in Bangladesh.

Methods: Healthy infants aged four to twelve weeks from urban slums in Bangladesh were randomized to one of three different intervention dosing arms (daily, weekly, biweekly - once every two weeks) of Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 over one month or to a fourth arm that received no probiotics. All subjects were followed for two additional months. Reported gastrointestinal and respiratory symptoms as well as breastfeeding rates, hospitalizations, differential withdrawals, and caretakers' perception of probiotic use were compared among arms.

Results: In total, 160 infants were randomized (40 to each arm) with 137 (Daily n = 35, Weekly n = 35, Biweekly n = 35, Control n = 32) followed up for a median of twelve weeks; 113 completed the study. Illness and breastfeeding rates were similar across all arms. Ten hospitalizations unrelated to probiotic use occurred. Forty eight percent of the caretakers of infants in intervention arms believed that probiotics improved their baby's health.

Conclusions: These two commonly used probiotics appeared safe and well-accepted by Bangladeshi families.

Trial registration: ClinicalTrials.gov NCT01899378 . Registered July 10, 2013.

Figures

Fig. 1
Fig. 1
Study design and sampling scheme
Fig. 2
Fig. 2
Flow-chart of study screening, enrollment, and retention

References

    1. WHO/FAO. Health and nutritional properties of powder milk with live lactic acid bacteria. Córdoba, Argentina: WHO/FAO; 2001.
    1. Thomas DW, Greer FR. Nutrition AAoPCo, American Academy of Pediatrics Section on Gastroenterology H, and Nutrition: Probiotics and prebiotics in pediatrics. Pediatrics. 2010;126(6):1217–31. doi: 10.1542/peds.2010-2548.
    1. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis. 2009;15(2):300–10. doi: 10.1002/ibd.20602.
    1. Lin A, Bik EM, Costello EK, Dethlefsen L, Haque R, Relman DA, et al. Distinct distal gut microbiome diversity and composition in healthy children from Bangladesh and the United States. PLoS One. 2013;8(1) doi: 10.1371/journal.pone.0053838.
    1. Mckay S, Gaudier E, Campbell DI, Prentice AM, Albers R. Environmental enteropathy: new targets for nutritional interventions. Int Health. 2010;2(3):172–80. doi: 10.1016/j.inhe.2010.07.006.
    1. Reid G, Anand S, Bingham MO, Mbugua G, Wadstrom T, Fuller R, et al. Probiotics for the developing world. J Clin Gastroenterol. 2005;39(6):485–8. doi: 10.1097/01.mcg.0000165648.32371.38.
    1. Topcuoglu S, Gursoy T, Ovalı F, Serce O, Karatekin G. A new risk factor for neonatal vancomycin-resistant Enterococcus colonisation: bacterial probiotics. J Matern Fetal Neonatal Med. 2014;1–4.
    1. Deshpande GC, Rao SC, Keil AD, Patole SK. Evidence-based guidelines for use of probiotics in preterm neonates. BMC Med. 2011;9:92. doi: 10.1186/1741-7015-9-92.
    1. Heimbach J, BioGaia AB. GRAS Notice 000254: Generally Recognized as Safe (GRAS) Determination of Lactobacillus reuteri Strain DSM 17938 Center for Food Safety and Applied Nutrition, Food and Drug Administration 2008:1–134
    1. Weizman Z, Alsheikh A. Safety and tolerance of a probiotic formula in early infancy comparing two probiotic agents: a pilot study. J Am Coll Nutr. 2006;25(5):415–9. doi: 10.1080/07315724.2006.10719554.
    1. Mangalat N, Liu Y, Fatheree NY, Ferris MJ, Van Arsdall MR, Chen Z, et al. Safety and tolerability of Lactobacillus reuteri DSM 17938 and effects on biomarkers in healthy adults: results from a randomized masked trial. PLoS One. 2012;7(9) doi: 10.1371/journal.pone.0043910.
    1. Oberhelman RA, Kosek MN, Penataro-Yori P, Paredes-Olortegui M, Connolly E. A Phase One Safety Study of Lactobacillus reuteri Conducted in the Peruvian Amazon: Observations from the Field. Am J Trop Med Hyg. 2014;90(4):777–80. doi: 10.4269/ajtmh.13-0639.
    1. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics. 2005;115(1):5–9.
    1. Gutierrez-Castrellon P, Lopez-Velazquez G, Diaz-Garcia L, Jimenez-Gutierrez C, Mancilla-Ramirez J, Estevez-Jimenez J, et al. Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial. PEDIATRICS. 2014;133(4):e904–9. doi: 10.1542/peds.2013-0652.
    1. Dinleyici EC, Dalgic N, Guven S, Metin O, Yasa O, Kurugol Z, et al. Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting. J Pediatr. 2015;91(4):392–6. doi: 10.1016/j.jped.2014.10.009.
    1. Savino F, Fornasero S, Ceratto S, De Marco A, Mandras N, Roana J, et al. Probiotics and gut health in infants: A preliminary case–control observational study about early treatment with Lactobacillus reuteri DSM 17938. Clin Chim Acta. 2015;451(Pt A):82–7. doi: 10.1016/j.cca.2015.02.027.
    1. Romani Vestman N, Chen T, Lif Holgerson P, Öhman C, Johansson I. Oral Microbiota Shift after 12-Week Supplementation with Lactobacillus reuteri DSM 17938 and PTA 5289. Randomized Control Trial PloS one. 2015;10(5) doi: 10.1371/journal.pone.0125812.
    1. Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2013;162(2):257–62. doi: 10.1016/j.jpeds.2012.08.004.
    1. Savino F, Cordisco L, Tarasco V, Palumeri E, Calabrese R, Oggero R, et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics. 2010;126(3):e526–33. doi: 10.1542/peds.2010-0433.
    1. Chau K, Lau E, Greenberg S, Jacobson S, Yazdani-Brojeni P, Verma N, et al. Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J Pediatr. 2015;166(1):74–8. doi: 10.1016/j.jpeds.2014.09.020.
    1. Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Maurogiovanni G, Bucci N, et al. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter. 2008;13(2):127–34. doi: 10.1111/j.1523-5378.2008.00593.x.
    1. Coccorullo P, Strisciuglio C, Martinelli M, Miele E, Greco L, Staiano A. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. J Pediatr. 2010;157(4):598–602. doi: 10.1016/j.jpeds.2010.04.066.
    1. Romano C. Ferrau’ V, Cavataio F, Iacono G, Spina M, Lionetti E, et al. Lactobacillus reuteri in children with functional abdominal pain (FAP) J Paediatr Child Health. 2014;50(10):E68–71. doi: 10.1111/j.1440-1754.2010.01797.x.
    1. Agustina RB-OI, Lukito W, Fahmida U, van de Rest O, Zimmermann MB, Firmansyah A, et al. Probiotics Lactobacillus reuteri DSM 17938 and Lactobacillus casei CRL 431 modestly increase growth, but not iron and zinc status, among Indonesian children aged 1–6 years. J Nutr. 2013;143(7):1184–93. doi: 10.3945/jn.112.166397.
    1. Grönlund M-M, Gueimonde M, Laitinen K, Kociubinski G, Grönroos T, Salminen S, et al. Maternal breast-milk and intestinal bifidobacteria guide the compositional development of the Bifidobacterium microbiota in infants at risk of allergic disease. Clin Exp Allergy. 2007;37(12):1764–72. doi: 10.1111/j.1365-2222.2007.02849.x.
    1. Proctor and Gamble Company. New Dietary Ingrediant Notification Information - Bifidobacterium infantis 35624. In: US Regulatory Affairs. April 29, 2005.
    1. Lin A, Luby S. Personal communication - unpublished data from the WASH Benefits Study. 2013
    1. WHO. Global Strategy for Infant and Young Child Feeding. 2000, 1–5:1–37.
    1. Hartung C, Anokwa Y, Brunette W, Lerer A, Tseng C, Borriello G. Open Data Kit: Tools to Build Information Services for Developing Regions. ICTD. 2010;1–11.
    1. WHO Infant and young child nutrition: Global strategy on infant and young child feeding. Fifty-Fifth World Health Assembly. Provisional Agenda Item. 2002;13.10(A55/15):1–18.
    1. Floch MH. Probiotic safety and risk factors. J Clin Gastroenterol. 2013;47(5):375–6. doi: 10.1097/MCG.0b013e3182840226.
    1. Boyle RJ, Robins-Browne RM, Tang MLK. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83(6):1256–64.
    1. Liong M-T. Safety of probiotics: translocation and infection. Nutr Rev. 2008;66(4):192–202. doi: 10.1111/j.1753-4887.2008.00024.x.
    1. Sarker SA, Sultana S, Fuchs GJ, Alam NH, Azim T, Brüssow H, et al. Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh. PEDIATRICS. 2005;116(2):e221–8. doi: 10.1542/peds.2004-2334.
    1. Matsuda F, Chowdhury MI, Saha A, Asahara T, Nomoto K, Tarique AA, et al. Evaluation of a probiotics, Bifidobacterium breve BBG-01, for enhancement of immunogenicity of an oral inactivated cholera vaccine and safety: a randomized, double-blind, placebo-controlled trial in Bangladeshi children under 5 years of age. Vaccine. 2011;29(10):1855–8. doi: 10.1016/j.vaccine.2010.12.133.
    1. Neu J. The developing intestinal microbiome: probiotics and prebiotics. World Rev Nutr Diet. 2014;110:167–76. doi: 10.1159/000358465.
    1. Murgas Torrazza R, Neu J. The developing intestinal microbiome and its relationship to health and disease in the neonate. J Perinatol. 2011;31(Suppl 1):S29–34. doi: 10.1038/jp.2010.172.
    1. Cox Laura M, Yamanishi S, Sohn J, Alekseyenko Alexander V, Leung Jacqueline M, Cho I, et al. Altering the Intestinal Microbiota during a Critical Developmental Window Has Lasting Metabolic Consequences. Cell. 2014;158(4):705–21. doi: 10.1016/j.cell.2014.05.052.
    1. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9(5):313–23. doi: 10.1038/nri2515.
    1. Arrieta M-C, Stiemsma LT, Amenyogbe N, Brown EM, Finlay B. The intestinal microbiome in early life: health and disease. Front Immunol. 2014;5:427. doi: 10.3389/fimmu.2014.00427.
    1. Timmerman HM, Koning CJM, Mulder L, Rombouts FM, Beynen AC. Monostrain, multistrain and multispecies probiotics--A comparison of functionality and efficacy. Int J Food Microbiol. 2004;96(3):219–33. doi: 10.1016/j.ijfoodmicro.2004.05.012.
    1. Gardiner GE, Casey PG, Casey G, Lynch PB, Lawlor PG, Hill C, et al. Relative ability of orally administered Lactobacillus murinus to predominate and persist in the porcine gastrointestinal tract. Appl Environ Microbiol. 2004;70(4):1895–906. doi: 10.1128/AEM.70.4.1895-1906.2004.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다